title: The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells.
abstract: The present study investigated the effects of the multikinase inhibitor sorafenib on androgen-independent cancer cells viability and intracellular signaling. Human androgen-independent PC-3 prostate cancer cells were treated with sorafenib. At concentration that suppresses extracellular signal-regulated kinase phosphorylation, sorafenib treatment reduced the mitochondrial transmembrane potential. Sorafenib also down-modulated the levels of myeloid cell leukemia 1, survivin and cellular inhibitor of apoptosis protein 2. Sorafenib induced caspase-3 cleavage and the mitochondrial release of cytochrome c. However, no nuclear translocation of apoptosis inducing factor was detected after treatment and the pan-caspase inhibitor Z-VAD-FMK had an obvious protective effect against the drug. In conclusion, sorafenib induces apoptosis through a caspase-dependent mechanism with down-regulated anti-apoptotic proteins in androgen-independent prostate cancer cells in vitro.
authors.affiliation: Department of Nuclear Medicine, National Key Discipline of Medical Imaging and Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Huang
authors.forename: Xue-Qin
authors.initials: XQ
authors.lastname: Chen
authors.forename: Ying
authors.initials: Y
authors.lastname: Huang
authors.forename: Ni
authors.initials: N
authors.lastname: Chen
authors.forename: Hao
authors.initials: H
authors.lastname: Zeng
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D001557:Benzenesulfonates / Q000494:pharmacology*; D053148:Caspase 3 / Q000378:metabolism; D020169:Caspases / Q000378:metabolism*; D045744:Cell Line, Tumor; D045304:Cytochromes c / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism; D008297:Male; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D008928:Mitochondria / Q000187:drug effects; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010766:Phosphorylation; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology*; D000077157:Sorafenib; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D001557:Benzenesulfonates; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D010671:Phenylurea Compounds; D019253:Proto-Oncogene Proteins c-bcl-2; D011725:Pyridines; D000077022:Survivin; D009536:Niacinamide; D045304:Cytochromes c; D000077157:Sorafenib; D048049:Extracellular Signal-Regulated MAP Kinases; D053148:Caspase 3; D020169:Caspases
references.citation: J Cell Sci. 2002 Dec 15;115(Pt 24):4727-34
references.pmid: 12432061
references.citation: Annu Rev Cell Dev Biol. 1999;15:269-90
references.pmid: 10611963
references.citation: Cell. 2002 Oct 18;111(2):147-50
references.pmid: 12408857
references.citation: Br J Cancer. 2007 Dec 3;97(11):1480-5
references.pmid: 18040273
references.citation: CA Cancer J Clin. 2005 Sep-Oct;55(5):300-18; quiz 323-5
references.pmid: 16166075
references.citation: Oncogene. 2005 Apr 7;24(15):2474-82
references.pmid: 15735703
references.citation: J Cell Biochem. 2000 Sep 7;79(3):355-69
references.pmid: 10972974
references.citation: Eur Cytokine Netw. 2001 Oct-Dec;12(4):654-63
references.pmid: 11781193
references.citation: Cancer Res. 2008 Aug 1;68(15):6109-17
references.pmid: 18676833
references.citation: Cancer Cell. 2006 May;9(5):328-30
references.pmid: 16697952
references.citation: Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
references.pmid: 17126425
references.citation: Rev Urol. 2007;9 Suppl 2:S3-S12
references.pmid: 17554403
references.citation: J Biol Chem. 2005 Oct 21;280(42):35217-27
references.pmid: 16109713
references.citation: Clin Cancer Res. 2007 Aug 15;13(16):4934-42
references.pmid: 17652623
references.citation: Neoplasia. 2000 May-Jun;2(3):235-41
references.pmid: 10935509
references.citation: Clin Cancer Res. 2008 Jan 1;14(1):209-14
references.pmid: 18172272
references.citation: Asian J Androl. 2008 Jul;10(4):635-41
references.pmid: 18097517
references.citation: Cancer Cell. 2007 Jul;12(1):66-80
references.pmid: 17613437
references.citation: Ann Oncol. 2008 Apr;19(4):746-51
references.pmid: 18056648
references.citation: Urology. 2005 Jun;65(6 Suppl):2-7
references.pmid: 15939076
references.citation: EMBO J. 1997 Dec 1;16(23):6914-25
references.pmid: 9384571
references.citation: Nature. 1999 Feb 4;397(6718):441-6
references.pmid: 9989411
references.citation: Asian J Androl. 2009 Jan;11(1):9-13
references.pmid: 19050685
references.citation: Int J Cancer. 2007 Aug 1;121(3):520-7
references.pmid: 17415712
references.citation: Cancer Res. 2005 Mar 15;65(6):2412-21
references.pmid: 15781657
references.citation: Mol Cell Biol. 2007 Aug;27(15):5499-513
references.pmid: 17548474
references.citation: Int Rev Cytol. 2005;247:35-88
references.pmid: 16344111
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Oncogene. 2005 Oct 20;24(46):6861-9
references.pmid: 16007148
references.citation: FEBS Lett. 2000 Jul 7;476(3):118-23
references.pmid: 10913597
references.citation: J Cell Physiol. 2003 Oct;197(1):8-29
references.pmid: 12942537
references.citation: Am J Pathol. 1996 May;148(5):1567-76
references.pmid: 8623925
references.citation: Oncogene. 2007 May 3;26(20):2822-32
references.pmid: 17072336
references.citation: J Clin Oncol. 2005 Feb 10;23(5):965-72
references.pmid: 15613696
references.citation: Oncogene. 2004 Apr 12;23(16):2785-96
references.pmid: 15077142
references.citation: Cancer Res. 2006 Feb 1;66(3):1611-9
references.pmid: 16452220
references.citation: Cancer Res. 2004 Oct 1;64(19):7099-109
references.pmid: 15466206
references.citation: BJU Int. 2009 Jun;103(12):1636-40
references.pmid: 19154507
references.citation: Prostate. 2005 Sep 15;65(1):10-9
references.pmid: 15799033